Cargando…
Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
BACKGROUND: Recently, histopathological tumour regression, prevalence of signet ring cells, and localisation were reported as prognostic factors in neoadjuvantly treated oesophagogastric (junctional and gastric) cancer. This exploratory retrospective study analyses independent prognostic factors wit...
Autores principales: | Schmidt, T, Sicic, L, Blank, S, Becker, K, Weichert, W, Bruckner, T, Parakonthun, T, Langer, R, Büchler, M W, Siewert, J-R, Lordick, F, Ott, K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974097/ https://www.ncbi.nlm.nih.gov/pubmed/24569472 http://dx.doi.org/10.1038/bjc.2014.94 |
Ejemplares similares
-
A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients
por: Blank, Susanne, et al.
Publicado: (2014) -
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy
por: Aichler, Michaela, et al.
Publicado: (2014) -
Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022) -
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
por: Noble, F, et al.
Publicado: (2017) -
ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
por: Reynolds, JV, et al.
Publicado: (2017)